Precision Therapy in RAS Mutant Colorectal Cancer

Gastroenterology. 2020 Mar;158(4):806-811. doi: 10.1053/j.gastro.2019.12.051. Epub 2020 Jan 21.

Authors

Rodrigo Dienstmann¹, Kate Connor², Annette T Byrne²; COLOSSUS Consortium

Collaborators

COLOSSUS Consortium:
W H Fridman, D Lambrechts, A Sadanandam, L Trusolino, J H M Prehn, J Tabernero, W Kolch

Affiliations

¹ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
² Royal College of Surgeons in Ireland, Dept of Physiology and Medical Physics, RCSI Centre for Systems Medicine, Dublin 2, Ireland.

PMID: 31972237
DOI: 10.1053/j.gastro.2019.12.051

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials as Topic
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics
Drug Resistance, Neoplasm / drug effects*
Drug Resistance, Neoplasm / genetics
GTP Phosphohydrolases / antagonists & inhibitors
GTP Phosphohydrolases / genetics
Gain of Function Mutation
Humans
MAP Kinase Signaling System / drug effects
MAP Kinase Signaling System / genetics
Membrane Proteins / antagonists & inhibitors
Membrane Proteins / genetics
Microsatellite Instability
Mutation, Missense
Precision Medicine / methods*
Protein Kinase Inhibitors / pharmacology*
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors
Proto-Oncogene Proteins p21(ras) / genetics
Treatment Outcome

Substances

KRAS protein, human
Membrane Proteins
Protein Kinase Inhibitors
GTP Phosphohydrolases
NRAS protein, human
HRAS protein, human
Proto-Oncogene Proteins p21(ras)